KRAS and non-small cell lung carcinoma: In addition, KRAS p.G12C has been documented as a sensitizing mutation associated with responsiveness to the oral RAS-GTPase inhibitor sotorasib, offering an additional therapeutic option for the targeted treatment of NSCLC [29].